Perfil
Jeff S.
Hartness currently works at Corganics LP, as Director from 2022, Bryn Pharma LLC, as Director from 2022, and Apogee Therapeutics, Inc., as Chief Commercial Officer from 2024.
Mr. Hartness also formerly worked at Bausch Health Cos., Inc., as Executive VP-Generics and Government Affairs.
Mr. Hartness received his undergraduate degree from Hanover College.
Cargos activos de Jeff Hartness
| Empresas | Cargo | Inicio |
|---|---|---|
| APOGEE THERAPEUTICS, INC. | Corporate Officer/Principal | 09/09/2024 |
Corganics LP
Corganics LP Medical DistributorsDistribution Services Manufactures and distributes natural topical pain analgesic cream | Director/Miembro de la Junta | 23/02/2022 |
Bryn Pharma LLC
Bryn Pharma LLC Medical SpecialtiesHealth Technology Develops bi-dose intranasal devices for patients with anaphylaxis | Director/Miembro de la Junta | 13/12/2022 |
Antiguos cargos conocidos de Jeff Hartness.
| Empresas | Cargo | Fin |
|---|---|---|
| BAUSCH HEALTH COMPANIES INC. | Consejero General | - |
Formación de Jeff Hartness.
Experiencias
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Relaciones
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
Empresas relacionadas
| Empresas privadas | 5 |
|---|---|
Hanover College
Hanover College Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Bausch Health Cos., Inc.
Bausch Health Cos., Inc. Pharmaceuticals: OtherHealth Technology Manufactures and markets pharmaceutical products | Health Technology |
Corganics LP
Corganics LP Medical DistributorsDistribution Services Manufactures and distributes natural topical pain analgesic cream | Distribution Services |
Bryn Pharma LLC
Bryn Pharma LLC Medical SpecialtiesHealth Technology Develops bi-dose intranasal devices for patients with anaphylaxis | Health Technology |
Apogee Therapeutics, Inc.
Apogee Therapeutics, Inc. BiotechnologyHealth Technology Operates as a clinical stage biotechnology company that develops therapies for immunological and inflammatory disorders | Health Technology |
- Bolsa de valores
- Insiders
- Jeff Hartness
















